ClinicalTrials.gg
Not yet recruitingNCT07947368Updated Nov 19, 2026

Study to Evaluate the Effect of Crinecerfont on Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia (CAH)

A Phase 3 interventional study of Crinecerfont in Congenital Adrenal Hyperplasia, sponsored by Neurocrine Biosciences. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences — 3 open to participants now, 6 under way, 3 of them phase 3. Adrenal Hyperplasia, Congenital · Neurocrine Biosciences.

Planned enrollment
4th of 17
100 · median 28
Started
2026
with 2 others
Phase 3
7 of 17
1 open now
Registered
17th of 17
by date

Among the 17 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences, this one is the 4th largest by planned enrollment, is one of 3 that started in 2026, is one of 7 in phase 3, and was the 17th registered.

Adrenal Hyperplasia, Congenital

101 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 28 are open to participants now.

Browse Adrenal Hyperplasia, Congenital studies →

Open to participants now

3 of the 17 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 20 Adrenal Hyperplasia, Congenital studies recruiting now, 10 (50%) set no upper age limit and 9 (45%) stop at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Adrenal Hyperplasia, Congenital by Neurocrine Biosciences, or all of them as a file.
02

Study summary

The study will evaluate the effect of crinecerfont on elevated androstenedione levels in adults with classic CAH on a stable glucocorticoid (GC) dose.

03

Conditions studied

  • Congenital Adrenal Hyperplasia

Keywords

  • Congenital Adrenal Hyperplasia
  • CAH
  • Crinecerfont
  • Classic Congenital Adrenal Hyperplasia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Be ≥18 years of age (all participants). Female participants must also be ≤45 years of age.
  • Have a medically confirmed diagnosis of classic 21-hydroxylase deficiency (21-OHD) CAH.
  • Have elevated androstenedione level at screening.
  • Be on a stable GC dose regimen that includes a morning dose of GC.

Key Exclusion Criteria:

  • Have a known or suspected diagnosis of any of the other forms of classic CAH.
  • Have a history of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic therapy with oral GCs, or requiring chronic therapy with inhaled GCs.
  • Have a medical condition or chronic disease that in the opinion of the investigator would preclude the participant from participating in and completing the study or that could confound interpretation of study outcomes.

Note: Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Crinecerfont

    Participants will receive crinecerfont during the overall treatment period.

    Drug: Crinecerfont

Interventions

  • DrugCrinecerfont

    Oral administration

    Also known as: Crenessity

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Serum Androstenedione at Week 24

    Time frame: Baseline, Week 24

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jan 2028, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 19, 2026
StartEst.
Nov 2026
Primary completionEst.
Jan 2028
CompletionEst.
Jul 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947368
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Neurocrine Medical Information Call Center
Contact
medinfo@neurocrine.com
1-877-641-3461
Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion